ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, S. R.
Eur Respir J 2006; 27:1056-1065
Copyright ©ERS Journals Ltd 2006

Lymphangioleiomyomatosis

S. R. Johnson

Division of Therapeutics and Molecular Medicine, University Hospital, Queens Medical Centre, Nottingham, UK.

CORRESPONDENCE: S. R. Johnson, Division of Therapeutics and Molecular Medicine, University Hospital, Queens Medical Centre, Nottingham NG7 2UH, UK. Fax: 44 1159422232. E-mail: simon.johnson{at}nottingham.ac.uk

Keywords: Angiomyolipoma, interstitial disease, orphan disease, tuberous sclerosis

Received: October 9, 2003
Accepted March 31, 2004

Lymphangioleiomyomatosis (LAM) is a rare disease of the lungs and lymphatics, which can occur sporadically or in association with tuberous sclerosis. LAM almost exclusively affects females, generally developing before the menopause.

The disease is characterised by progressive pulmonary cystic change, recurrent pneumothorax, chylous pleural collections and, in most cases, progressive respiratory failure. Abdominal manifestations include lymphadenopathy, cystic lymphatic masses (lymphangioleiomyomas), chylous ascites and angiomyolipoma (a benign tumour). Survival in LAM is ~70% at 10 yrs, although this is highly variable since long-term survivors have been described.

Diagnosis is made by a combination of clinical features and computed tomography scanning or, in cases of doubt, lung biopsy. In patients with rapidly progressive disease, hormone treatment (predominantly progesterone) has been used, although no firm evidence supports its use. Otherwise, treatment is aimed at complications including pneumothorax, chylous collections and extrapulmonary manifestations. The only treatment for severe LAM is currently lung transplantation.

Recent developments in the cell biology of lymphangioleiomyomatosis have shown that these patients have somatic mutations in the genes linked to tuberous sclerosis and that rapamycin may correct the resulting cellular abnormality. Trials of rapamycin in lymphangioleiomyomatosis are currently underway and offer hope of evidence-based treatment for the disease.




This article has been cited by other articles:


Home page
 Ann. N. Y. Acad. Sci.Home page
C. G. GLASGOW, A. M. TAVEIRA-DASILVA, T. N. DARLING, and J. MOSS
Lymphatic Involvement in Lymphangioleiomyomatosis
Ann. N.Y. Acad. Sci., May 1, 2008; 1131(1): 206 - 214.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. K. Glassberg, S. J. Elliot, J. Fritz, P. Catanuto, M. Potier, R. Donahue, W. Stetler-Stevenson, and M. Karl
Activation of the Estrogen Receptor Contributes to the Progression of Pulmonary Lymphangioleiomyomatosis via Matrix Metalloproteinase-Induced Cell Invasiveness
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1625 - 1633.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. A. Goncharova, D. A. Goncharov, A. Chisolm, M. S. Spaits, P. N. Lim, G. Cesarone, I. Khavin, O. Tliba, Y. Amrani, R. A. Panettieri Jr., et al.
Interferon {beta} Augments Tuberous Sclerosis Complex 2 (TSC2)-Dependent Inhibition of TSC2-Null ELT3 and Human Lymphangioleiomyomatosis-Derived Cell Proliferation
Mol. Pharmacol., March 1, 2008; 73(3): 778 - 788.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. X. McCormack
Lymphangioleiomyomatosis: A Clinical Update
Chest, February 1, 2008; 133(2): 507 - 516.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. R. Young, Y. Inoue, and F. X. McCormack
Diagnostic Potential of Serum VEGF-D for Lymphangioleiomyomatosis
N. Engl. J. Med., January 10, 2008; 358(2): 199 - 200.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
V. P. Krymskaya
Smooth Muscle like Cells in Pulmonary Lymphangioleiomyomatosis
Proceedings of the ATS, January 1, 2008; 5(1): 119 - 126.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
H. Watz, K. Engels, S. Loeschke, M. Amthor, D. Kirsten, and H. Magnussen
Lymphangioleiomyomatosis--presence of receptor tyrosine kinases and the angiogenesis factor VEGF-A as potential therapeutic targets
Thorax, June 1, 2007; 62(6): 559 - 559.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D'Armiento, K. Imai, J. Schiltz, N. Kolesnekova, D. Sternberg, K. Benson, A. Pardo, M. Selman, T. Smolarek, M. Vundavalli, et al.
Identification of the Benign Mesenchymal Tumor Gene HMGA2 in Lymphangiomyomatosis
Cancer Res., March 1, 2007; 67(5): 1902 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Zarogiannis, C. Hatzoglou, P. A. Molyvdas, and K. Gourgoulianis
Lymphangioleiomyomatosis
Eur. Respir. J., December 1, 2006; 28(6): 1284 - 1284.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
T. B. L. Ho, J. H. Hull, and N. C. Hughes
An 86-year-old female with lymphangioleiomyomatosis.
Eur. Respir. J., November 1, 2006; 28(5): 1065 - 1064.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
C. Vogelmeier and U. Costabel
Much ado about nothing?
Eur. Respir. J., May 1, 2006; 27(5): 880 - 880.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the European Respiratory Society.